Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Rating Reaffirmed by HC Wainwright

Day One Biopharmaceuticals (NASDAQ:DAWN)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They currently have a $50.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 200.48% from the stock’s previous close.

Other research analysts have also recently issued reports about the company. Oppenheimer reaffirmed a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. Needham & Company LLC raised their price objective on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday. Piper Sandler reiterated an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. JPMorgan Chase & Co. increased their target price on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a report on Monday. Finally, The Goldman Sachs Group dropped their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.67.

Day One Biopharmaceuticals Stock Up 8.2 %

DAWN opened at $16.64 on Wednesday. The stock has a market cap of $1.45 billion, a PE ratio of -6.99 and a beta of -1.48. Day One Biopharmaceuticals has a 52 week low of $9.67 and a 52 week high of $17.85. The business’s fifty day simple moving average is $15.27 and its 200 day simple moving average is $13.78.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). As a group, equities analysts anticipate that Day One Biopharmaceuticals will post -2.66 earnings per share for the current year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 2,666 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $40,656.50. Following the completion of the transaction, the chief financial officer now owns 277,754 shares of the company’s stock, valued at $4,235,748.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 2,666 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $40,656.50. Following the completion of the transaction, the chief financial officer now owns 277,754 shares of the company’s stock, valued at $4,235,748.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Samuel C. Blackman sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $16.11, for a total transaction of $322,200.00. Following the sale, the insider now directly owns 1,224,662 shares of the company’s stock, valued at approximately $19,729,304.82. The disclosure for this sale can be found here. Over the last quarter, insiders sold 55,781 shares of company stock valued at $883,160. Corporate insiders own 8.40% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. grew its position in Day One Biopharmaceuticals by 130.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock worth $27,000 after purchasing an additional 1,262 shares during the period. Quest Partners LLC purchased a new position in shares of Day One Biopharmaceuticals during the 4th quarter valued at $29,000. Quintet Private Bank Europe S.A. lifted its stake in shares of Day One Biopharmaceuticals by 43.2% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after buying an additional 1,000 shares in the last quarter. Amalgamated Bank lifted its stake in shares of Day One Biopharmaceuticals by 35.7% during the 3rd quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock valued at $106,000 after buying an additional 2,268 shares in the last quarter. Finally, Exchange Traded Concepts LLC lifted its stake in Day One Biopharmaceuticals by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock worth $147,000 after purchasing an additional 2,554 shares in the last quarter. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.